PE20211892A1 - Composicion liquida de clotrimazol envasada de dosis unica - Google Patents

Composicion liquida de clotrimazol envasada de dosis unica

Info

Publication number
PE20211892A1
PE20211892A1 PE2021001191A PE2021001191A PE20211892A1 PE 20211892 A1 PE20211892 A1 PE 20211892A1 PE 2021001191 A PE2021001191 A PE 2021001191A PE 2021001191 A PE2021001191 A PE 2021001191A PE 20211892 A1 PE20211892 A1 PE 20211892A1
Authority
PE
Peru
Prior art keywords
composition
peg
single dose
polyethylene
pharmaceutical
Prior art date
Application number
PE2021001191A
Other languages
English (en)
Inventor
Mendoza Maria Mar Terraz
Aquilue Javier Sanagustin
Molina Adolfo Tellez
Ganan Maria Isabel Delgado
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of PE20211892A1 publication Critical patent/PE20211892A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una composicion solucion liquida esteril farmaceutica o veterinaria, en donde dicha composicion comprende de 0,1% hasta 5% en peso (con respecto al volumen total de la composicion) de clotrimazol o una sal farmaceutica o veterinaria aceptable de este; un agente solubilizante seleccionado de polietilenglicol (PEG) tal como PEG 200, PEG 300, PEG 400, PEG 600 o una mezcla de los mismos, entre otros; y un contenido de agua igual o inferior a 4% en peso respecto al peso total de la composicion. Dicha composicion se encuentra en una unidad de envasado de dosis unica fabricado a partir de un polimero termoplastico seleccionado de polietileno (PE), polietileno de baja densidad (LDPE), polietileno de alta densidad (HDPE), polipropileno (PP) o una mezcla de los mismos, en donde dicha unidad de envasado de dosis unica es un envase soplado, llenado y sellado (blow-fill-seal, BFS) que tiene un volumen desde 0,05 mL hasta 8 mL. La composicion envasada de dosis unica de la presente invencion es esteril, homogenea y estable sin la presencia de conservantes que puedan causar efectos secundarios no deseados, permitiendo la administracion de una dosis mas exacta.
PE2021001191A 2019-02-19 2020-02-18 Composicion liquida de clotrimazol envasada de dosis unica PE20211892A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382120 2019-02-19
PCT/EP2020/054250 WO2020169611A1 (en) 2019-02-19 2020-02-18 Single-dose packaged clotrimazole liquid composition

Publications (1)

Publication Number Publication Date
PE20211892A1 true PE20211892A1 (es) 2021-09-22

Family

ID=65766941

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001191A PE20211892A1 (es) 2019-02-19 2020-02-18 Composicion liquida de clotrimazol envasada de dosis unica

Country Status (18)

Country Link
US (1) US20220133695A1 (es)
EP (1) EP3927310B1 (es)
JP (1) JP2022520714A (es)
KR (1) KR20210131313A (es)
CN (1) CN113423382A (es)
AU (1) AU2020225663B2 (es)
CA (1) CA3127151A1 (es)
CL (1) CL2021001882A1 (es)
CO (1) CO2021010326A2 (es)
CR (1) CR20210473A (es)
DO (1) DOP2021000169A (es)
IL (1) IL284858A (es)
MA (1) MA55007A (es)
MX (1) MX2021008803A (es)
PE (1) PE20211892A1 (es)
SG (1) SG11202107773RA (es)
WO (1) WO2020169611A1 (es)
ZA (1) ZA202105236B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240091268A1 (en) * 2022-09-07 2024-03-21 Combangio, Inc. Preparation and purification methods for mesenchymal stem cell derived secretome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
EP2094264A1 (en) * 2006-11-16 2009-09-02 E-Therapeutics Limited Clotrimazol for treating staphylococcal infections
DE102007056462B4 (de) * 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
MX337364B (es) * 2010-12-16 2016-02-29 Borje S Andersson Formulaciones farmaceuticas de azol para la administracion parenteral y metodos para preparar y usar las mismas como tratamiento de las enfermedades sensibles a los compuestos de azol.
US8933112B2 (en) * 2012-06-15 2015-01-13 Memphaceuticals, LLC Topical liquid to ameliorate pain and promote healing of burn-injured skin
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations

Also Published As

Publication number Publication date
CA3127151A1 (en) 2020-08-27
EP3927310C0 (en) 2024-04-10
KR20210131313A (ko) 2021-11-02
DOP2021000169A (es) 2021-09-30
CN113423382A (zh) 2021-09-21
ZA202105236B (en) 2023-10-25
EP3927310B1 (en) 2024-04-10
EP3927310A1 (en) 2021-12-29
MA55007A (fr) 2021-12-29
AU2020225663A1 (en) 2021-08-12
JP2022520714A (ja) 2022-04-01
SG11202107773RA (en) 2021-08-30
CL2021001882A1 (es) 2022-02-11
MX2021008803A (es) 2021-11-12
WO2020169611A1 (en) 2020-08-27
AU2020225663B2 (en) 2024-03-14
CO2021010326A2 (es) 2021-08-19
TW202045161A (zh) 2020-12-16
IL284858A (en) 2021-08-31
US20220133695A1 (en) 2022-05-05
CR20210473A (es) 2021-10-08

Similar Documents

Publication Publication Date Title
JP5711868B2 (ja) 安定なエダラボン含有水性製剤
JP2020203944A (ja) 眼科用水性組成物
CN102647971B (zh) 用于包含美洛昔康的组合物的容器
WO2018218013A9 (en) STERILIZABLE PHARMACEUTICAL PACKAGING FOR OPHTHALMIC FORMULATIONS
JP2022062078A5 (es)
PE20211892A1 (es) Composicion liquida de clotrimazol envasada de dosis unica
JP7262528B2 (ja) ジルチアゼムの非経口投薬形態
HRP20200039T1 (hr) Formulacija fosfomicina za parenteralnu primjenu
JP2023052927A (ja) 水性眼科組成物
JP2013231029A (ja) 既製のゲムシタビン注入溶液
JP2016155864A (ja) ピラゾロン化合物含有水溶液が充填されたプラスチック容器
ES2321875T3 (es) Preparacion oftalmica esteril,multifase, sin emulsionante aplicable en gotas.
CO2021002433A2 (es) Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente
RU2761519C2 (ru) Композиции на основе сложного холинового эфира липоевой кислоты и способы стабилизации с получением фармацевтически пригодных продуктов, представляющих собой лекарственное средство
JP2016022092A (ja) エダラボン含有プラスチック容器
JP2022191328A (ja) 水性組成物
JP2009143902A (ja) エダラボンを含有する安定な水溶性製剤
JP2006025953A (ja) ホリナート類水溶液充填プレフィルドシリンジ包装体
JP6081102B2 (ja) 安定なグラニセトロン含有水性製剤
ES2959975T3 (es) Forma de dosificación para infusión intravenosa de pemetrexed
Benabbes et al. 3PC-044 Paraffin oil-based emulsion: influence of gum arabic and the mixing rate on emulsion stability
JPWO2009075309A1 (ja) 製剤組成物
Beld et al. 3PC-043 New formulation of norepinephrine solution in prefilled cyclic olefin sterilised syringes
JP2023030691A (ja) 眼科組成物
ES2389373T3 (es) Disposición de aplicación para medicamentos que van a aplicarse sobre la piel y uso de un envase como disposición de aplicación